EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 103 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $38,836 | -24.0% | 43,300 | 0.0% | 0.00% | – |
| Q4 2022 | $51,094 | -81.1% | 43,300 | +20.3% | 0.00% | – |
| Q3 2022 | $271,000 | +29.7% | 36,000 | +8.4% | 0.00% | – |
| Q2 2022 | $209,000 | -14.3% | 33,200 | +12.9% | 0.00% | – |
| Q1 2022 | $244,000 | +59.5% | 29,400 | 0.0% | 0.00% | – |
| Q4 2021 | $153,000 | -26.8% | 29,400 | -6.1% | 0.00% | – |
| Q3 2021 | $209,000 | -21.7% | 31,300 | 0.0% | 0.00% | – |
| Q2 2021 | $267,000 | +0.4% | 31,300 | +4.3% | 0.00% | – |
| Q1 2021 | $266,000 | -27.9% | 30,000 | 0.0% | 0.00% | – |
| Q4 2020 | $369,000 | +51.2% | 30,000 | 0.0% | 0.00% | – |
| Q3 2020 | $244,000 | -15.3% | 30,000 | 0.0% | 0.00% | – |
| Q2 2020 | $288,000 | +119.8% | 30,000 | +55.4% | 0.00% | – |
| Q1 2020 | $131,000 | -14.4% | 19,300 | +87.4% | 0.00% | – |
| Q4 2019 | $153,000 | +44.3% | 10,300 | 0.0% | 0.00% | – |
| Q3 2019 | $106,000 | – | 10,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| P.A.W. CAPITAL CORP | 540,000 | $4,482,000 | 4.68% |
| Knoll Capital Management, LLC | 694,232 | $5,762,000 | 3.62% |
| Telemetry Investments, L.L.C. | 213,000 | $1,768,000 | 2.79% |
| ACT CAPITAL MANAGEMENT, LLC | 250,000 | $2,075,000 | 2.20% |
| VR Adviser, LLC | 1,469,767 | $12,199,000 | 1.98% |
| INTERWEST VENTURE MANAGEMENT CO | 560,990 | $4,656,000 | 1.78% |
| 683 Capital Management, LLC | 3,375,000 | $28,013,000 | 1.50% |
| Trellus Management Company, LLC | 300,000 | $2,490,000 | 1.45% |
| Altium Capital Management LP | 440,000 | $3,652,000 | 1.22% |
| CAXTON CORP | 116,884 | $970,000 | 1.21% |